The Shot Felt 'Round the World
12:00p.m. - 1:00p.m.
Penn Medicine researchers have developed a unifying definition of “cytokine storm” to provide a framework to assess and treat patients whose immune systems have gone rogue.
A new alteration to the way T cells are engineered has significant implications for using engineered T cells to fight both HIV and cancer.
Single cell sequencing aided researchers in identifying a previously undiscovered molecule in the brain.
The assistant professor of systems pharmacology and translational therapeutics, who studied with Carl June as a postdoctoral fellow, combines his two research passions—gene therapy and investigating ‘little known’ biology—in the pursuit of new knowledge.
Pairing their expertise, Nilam Mangalmurti of the Perelman School of Medicine and Christopher Hunter of the School of Veterinary Medicine have been working to understand the protective and harmful aspects of the immune response, including in COVID-19.
The researchers, from the Annenberg Public Policy Center and the Perelman School of Medicine, join a class of honored scholars recognized for their unique and ongoing contributions to original research.
Research led by the School of Veterinary Medicine’s Rumela Chakrabarti identified a molecular pathway responsible for the disease’s progression and spread.
While the world works to flatten the curve, scientists at Penn and Wistar hope to deliver the COVID-19 pandemic’s silver bullet: a vaccine that effectively protects people from infection.
Penn researchers have shown success using genetically engineered macrophages, an immune cell that eats invaders in the body, to target solid tumors.
A Penn study shows a better clinical response to immunotherapy correlates with higher ratio of tumor mutations detected by a liquid biopsy.
Una O’Doherty of the Perelman School of Medicine commented on a study that appeared to fully suppress HIV without using drugs. “It’s certainly encouraging but speculative,” she said. “I need to see more before I would say, ‘Oh, she’s cured.’”
FULL STORY →
Paul Offit of the Perelman School of Medicine said the benefits of a repurposed vaccines are limited. “We are much better off with a vaccine that induces specific immunity,” he said.
FULL STORY →